Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O43930

UPID:
PRKY_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O43930; O15348; O15349

BACKGROUND:
Putative serine/threonine-protein kinase PRKY is a pivotal enzyme in the regulation of cell signaling, impacting cell growth, division, and apoptosis. The enzyme's activity, through phosphorylation of serine and threonine, is essential for the proper functioning of numerous cellular processes. Research into PRKY's specific roles and interactions continues to unveil its complexities and importance.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Putative serine/threonine-protein kinase PRKY could open doors to potential therapeutic strategies. As research unfolds, the therapeutic implications of modulating PRKY's activity in various diseases become increasingly evident, positioning it as a promising target in the development of novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.